Cancer Tissue Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

Description

The global cancer tissue diagnostics market is set to witness substantial growth in the coming years, driven by increasing cancer prevalence, advancements in diagnostic technologies, and a growing focus on personalized medicine. The market is projected to expand at a CAGR of 6.60%, reaching USD 7.84 billion in 2025 and USD 12.26 billion by 2032.

Market Insights: Tissue diagnostics have become an indispensable tool in oncology, providing critical insights into cancer biology. These diagnostics enable precise cancer detection and treatment planning, significantly improving patient outcomes. Factors such as heightened cancer awareness, enhanced preventive healthcare measures, and technological advancements in digital pathology are contributing to the market's growth trajectory.

Market Growth Drivers:

Rising Cancer Prevalence: The increasing incidence of cancer worldwide is a primary growth driver for the cancer tissue diagnostics market.
Aging Population: A growing elderly demographic further contributes to cancer risk, necessitating advanced diagnostic solutions.
Technological Advancements: The integration of digital pathology, automation, and biomarker-based diagnostic tools is enhancing diagnostic precision.
Government and Private Initiatives: Cancer awareness programs, early screening initiatives, and research funding are positively impacting the market.

Market Restraints:

Shortage of Skilled Professionals: The lack of trained histologists and pathologists is a major challenge in the market.
Growing Adoption of Refurbished Diagnostic Equipment: Many healthcare institutions in developing regions prefer cost-effective refurbished imaging systems over new, advanced diagnostics.

Business Opportunities:

Emerging Biomarkers for Cancer Detection: The introduction of novel cancer biomarkers is expanding the scope of precision medicine and targeted therapies.
Increased Investment in Oncology Research: Continuous research and development (R&D) initiatives are fostering innovation in cancer diagnostics.
Expansion into Emerging Markets: Rising healthcare infrastructure and increasing investments in cancer care in Asia Pacific, Latin America, and the Middle East present lucrative opportunities for market players.

Regional Analysis:

North America: The region continues to dominate the global cancer tissue diagnostics market due to a high incidence of cancer, well-established healthcare infrastructure, and strong investment in research.
Europe: Increasing cancer cases, government initiatives, and advancements in diagnostic technologies are fueling market growth.
Asia Pacific: Rapid urbanization, a growing geriatric population, and increasing healthcare spending are driving significant growth in this region.
Latin America, Middle East, and Africa: Improving healthcare accessibility and rising cancer awareness are contributing to market expansion.

Key Players in the Market: Prominent market players are investing in technological advancements and strategic partnerships to strengthen their market position. Major companies include:

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Ventana Medical Systems, Inc.
Bio Rad Laboratories Inc.
Enzo Life Sciences, Inc.
Abcam plc.
BioGenex
Agilent Technologies, Inc.
PerkinElmer Inc.
Danaher Corporation
Sigma-Aldrich Co., LLC

Recent Developments:

Product Launches: In June 2020, F. Hoffmann-La Roche AG launched its uPath PD-L1 (SP263) digital pathology platform with CE-IVD certification for non-small cell lung cancer (NSCLC) research. In June 2022, Roche introduced the VENTANA DP 600, a high-capacity digital slide scanner designed to enhance pathology lab workflows and diagnostic accuracy.

Market Segmentation: The cancer tissue diagnostics market is segmented based on test type, in situ hybridization (ISH) tests, and regions.

By Test Type: Breast Cancer Stomach (Gastric) Cancer Colorectal Cancer Prostate Cancer Others
By In Situ Hybridization (ISH) Test: Breast Cancer Non-Small Cell Lung Cancer (NSCLC) Bladder Cancer Others
By Region: North America Europe Asia Pacific Latin America Middle East & Africa

1. Executive Summary

1.1. Global Cancer Tissue Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Economic Overview
- 2.6.1. World Economic Projections
2.7. PESTLE Analysis

3. Pricing Analysis, 2019 - 2023

3.1. Global Cancer Tissue Diagnostics, Pricing Analysis, by Region, 2019 - 2023
- 3.1.1. North America
- 3.1.2. Europe
- 3.1.3. Asia Pacific
- 3.1.4. Latin America
- 3.1.5. Middle East & Africa

4. Global Cancer Tissue Diagnostics Market Outlook, 2019 - 2032

4.1. Global Cancer Tissue Diagnostics Market Outlook, by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 4.1.1. Key Highlights
  - 4.1.1.1. Breast Cancer
  - 4.1.1.2. Stomach (Gastric) Cancer
  - 4.1.1.3. Colorectal Cancer
  - 4.1.1.4. Prostate Cancer
  - 4.1.1.5. Others
4.2. Global Cancer Tissue Diagnostics Market Outlook, by In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 4.2.1. Key Highlights
  - 4.2.1.1. Breast Cancer
  - 4.2.1.2. Non-Small Cell Lung Cancer (NSCLC)
  - 4.2.1.3. Bladder Cancer
  - 4.2.1.4. Others
4.3. Global Cancer Tissue Diagnostics Market Outlook, by Region, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 4.3.1. Key Highlights
  - 4.3.1.1. North America
  - 4.3.1.2. Europe
  - 4.3.1.3. Asia Pacific
  - 4.3.1.4. Latin America
  - 4.3.1.5. Middle East & Africa

5. North America Cancer Tissue Diagnostics Market Outlook, 2019 - 2032

5.1. North America Cancer Tissue Diagnostics Market Outlook, by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 5.1.1. Key Highlights
  - 5.1.1.1. Breast Cancer
  - 5.1.1.2. Stomach (Gastric) Cancer
  - 5.1.1.3. Colorectal Cancer
  - 5.1.1.4. Prostate Cancer
  - 5.1.1.5. Others
5.2. North America Cancer Tissue Diagnostics Market Outlook, by In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 5.2.1. Key Highlights
  - 5.2.1.1. Breast Cancer
  - 5.2.1.2. Non-Small Cell Lung Cancer (NSCLC)
  - 5.2.1.3. Bladder Cancer
  - 5.2.1.4. Others
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. North America Cancer Tissue Diagnostics Market Outlook, by Country, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 5.3.1. Key Highlights
  - 5.3.1.1. U.S. Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 5.3.1.2. U.S. Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 5.3.1.3. Canada Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 5.3.1.4. Canada Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Cancer Tissue Diagnostics Market Outlook, 2019 - 2032

6.1. Europe Cancer Tissue Diagnostics Market Outlook, by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 6.1.1. Key Highlights
  - 6.1.1.1. Breast Cancer
  - 6.1.1.2. Stomach (Gastric) Cancer
  - 6.1.1.3. Colorectal Cancer
  - 6.1.1.4. Prostate Cancer
  - 6.1.1.5. Others
6.2. Europe Cancer Tissue Diagnostics Market Outlook, by In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 6.2.1. Key Highlights
  - 6.2.1.1. Breast Cancer
  - 6.2.1.2. Non-Small Cell Lung Cancer (NSCLC)
  - 6.2.1.3. Bladder Cancer
  - 6.2.1.4. Others
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Europe Cancer Tissue Diagnostics Market Outlook, by Country, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 6.3.1. Key Highlights
  - 6.3.1.1. Germany Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.2. Germany Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.3. U.K. Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.4. U.K. Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.5. France Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.6. France Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.7. Italy Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.8. Italy Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.9. Turkey Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.10. Turkey Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.11. Russia Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.12. Russia Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.13. Rest of Europe Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 6.3.1.14. Rest of Europe Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Cancer Tissue Diagnostics Market Outlook, 2019 - 2032

7.1. Asia Pacific Cancer Tissue Diagnostics Market Outlook, by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 7.1.1. Key Highlights
  - 7.1.1.1. Breast Cancer
  - 7.1.1.2. Stomach (Gastric) Cancer
  - 7.1.1.3. Colorectal Cancer
  - 7.1.1.4. Prostate Cancer
  - 7.1.1.5. Others
7.2. Asia Pacific Cancer Tissue Diagnostics Market Outlook, by In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 7.2.1. Key Highlights
  - 7.2.1.1. Breast Cancer
  - 7.2.1.2. Non-Small Cell Lung Cancer (NSCLC)
  - 7.2.1.3. Bladder Cancer
  - 7.2.1.4. Others
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Asia Pacific Cancer Tissue Diagnostics Market Outlook, by Country, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 7.3.1. Key Highlights
  - 7.3.1.1. China Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.2. China Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.3. Japan Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.4. Japan Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.5. South Korea Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.6. South Korea Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.7. India Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.8. India Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.9. Southeast Asia Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.10. Southeast Asia Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.11. Rest of Asia Pacific Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 7.3.1.12. Rest of Asia Pacific Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Cancer Tissue Diagnostics Market Outlook, 2019 - 2032

8.1. Latin America Cancer Tissue Diagnostics Market Outlook, by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 8.1.1. Key Highlights
  - 8.1.1.1. Breast Cancer
  - 8.1.1.2. Stomach (Gastric) Cancer
  - 8.1.1.3. Colorectal Cancer
  - 8.1.1.4. Prostate Cancer
  - 8.1.1.5. Others
8.2. Latin America Cancer Tissue Diagnostics Market Outlook, by In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Latin America Cancer Tissue Diagnostics Market Outlook, by Country, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 8.3.1. Key Highlights
  - 8.3.1.1. Brazil Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.2. Brazil Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.3. Mexico Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.4. Mexico Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.5. Argentina Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.6. Argentina Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.7. Rest of Latin America Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 8.3.1.8. Rest of Latin America Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Cancer Tissue Diagnostics Market Outlook, 2019 - 2032

9.1. Middle East & Africa Cancer Tissue Diagnostics Market Outlook, by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 9.1.1. Key Highlights
  - 9.1.1.1. Breast Cancer
  - 9.1.1.2. Stomach (Gastric) Cancer
  - 9.1.1.3. Colorectal Cancer
  - 9.1.1.4. Prostate Cancer
  - 9.1.1.5. Others
9.2. Middle East & Africa Cancer Tissue Diagnostics Market Outlook, by In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 9.2.1. Key Highlights
  - 9.2.1.1. Breast Cancer
  - 9.2.1.2. Non-Small Cell Lung Cancer (NSCLC)
  - 9.2.1.3. Bladder Cancer
  - 9.2.1.4. Others
- 9.2.2. BPS Analysis/Market Attractiveness Analysis
9.3. Middle East & Africa Cancer Tissue Diagnostics Market Outlook, by Country, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 9.3.1. Key Highlights
  - 9.3.1.1. GCC Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.2. GCC Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.3. South Africa Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.4. South Africa Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.5. Egypt Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.6. Egypt Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.7. Nigeria Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.8. Nigeria Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.9. Rest of Middle East & Africa Cancer Tissue Diagnostics Market by Test Type, Volume (Units) and Value (US$ Bn), 2019 - 2032
  - 9.3.1.10. Rest of Middle East & Africa Cancer Tissue Diagnostics Market In Situ Hybridization (ISH) Test, Volume (Units) and Value (US$ Bn), 2019 - 2032
- 9.3.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

10.1. End Use vs In Situ Hybridization (ISH) Test Heatmap
10.2. Manufacturer vs In Situ Hybridization (ISH) Test Heatmap
10.3. Company Market Share Analysis, 2024
10.4. Competitive Dashboard
10.5. Company Profiles
- 10.5.1. Abbott Laboratories
  - 10.5.1.1. Company Overview
  - 10.5.1.2. Product Portfolio
  - 10.5.1.3. Financial Overview
  - 10.5.1.4. Business Strategies and Development
- 10.5.2. F. Hoffmann-La Roche Ltd.
- 10.5.3. Thermo Fisher Scientific Inc.
- 10.5.4. Ventana Medical Systems, Inc.
- 10.5.5. Bio Rad Laboratories Inc.
- 10.5.6. Enzo Life Sciences, Inc.
- 10.5.7. Abcam plc.
- 10.5.8. BioGenex
- 10.5.9. Cell Signalling Technology, Inc.
- 10.5.10. Agilent Technologies, Inc.
- 10.5.11. PerkinElmer Inc.
- 10.5.12. Bio SB
- 10.5.13. Cancer Genetics Inc.
- 10.5.14. Danaher Corporation
- 10.5.15. ROSETTA GENOMICS
- 10.5.16. Nanoprobes, Inc.
- 10.5.17. Creative-Biolabs
- 10.5.18. Enzo Life Sciences, Inc.
- 10.5.19. Sigma-Aldrich Co., LLC

11. Appendix

11.1. Research Methodology
11.2. Report Assumptions
11.3. Acronyms and Abbreviations